In the last trading session, 1.05 million shares of the Denali Therapeutics Inc (NASDAQ:DNLI) were traded, and its beta was 1.41. Most recently the company’s share price was $20.88, and it changed around -$1.37 or -6.16% from the last close, which brings the market valuation of the company to $3.01B. DNLI currently trades at a discount to its 52-week high of $33.33, offering almost -59.63% off that amount. The share price’s 52-week low was $14.56, which indicates that the current value has risen by an impressive 30.27% since then. We note from Denali Therapeutics Inc’s average daily trading volume that its 10-day average is 0.87 million shares, with the 3-month average coming to 964.34K.
Denali Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.18. If we narrow it down even further, the data shows that 0 out of 18 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 1 recommended DNLI as a Hold, whereas 13 deemed it a Buy, and 0 rated it as Underweight. Denali Therapeutics Inc is expected to report earnings per share of -0.89 for the current quarter.
Denali Therapeutics Inc (NASDAQ:DNLI) trade information
Instantly DNLI has showed a red trend with a performance of -6.16% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 24.34 on recent trading dayincreased the stock’s daily price by 14.22%. The company’s shares are currently up 2.45% year-to-date, but still down -4.40% over the last five days. On the other hand, Denali Therapeutics Inc (NASDAQ:DNLI) is -1.74% down in the 30-day period. We can see from the shorts that 7.97 million shares have been sold at a short interest cover period of 7.03 day(s).
The consensus price target as assigned by Wall Street analysts is $32.5, which translates to bulls needing to increase their stock price by 35.75% from its current value. Analyst projections state that DNLI is forecast to be at a low of $22 and a high of $46.
Denali Therapeutics Inc (DNLI) estimates and forecasts
The year-over-year growth rate is expected to be -97.00%, down from the previous year.
Consensus estimates provided by 13 financial analysts predict the company will bring in an average of 9.88M in revenue for the current quarter. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -21.99%.
DNLI Dividends
Denali Therapeutics Inc’s next quarterly earnings report is expected to be released in March.
Denali Therapeutics Inc (NASDAQ:DNLI)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 9.68% of Denali Therapeutics Inc shares, and 90.85% of them are in the hands of institutional investors. The stock currently has a share float of 100.59%. Denali Therapeutics Inc stock is held by 332.0 institutions, with BAILLIE GIFFORD & CO being the largest institutional investor. By 2024-06-30, it held 9.2123% of the shares, which is about 13.76 million shares worth $319.59 million.
BLACKROCK INC., with 8.8181% or 13.17 million shares worth $305.91 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Specialized-Health Care Fund and Smallcap World Fund were the top two Mutual Funds as of Oct 31, 2024 . The former held 8.8 shares worth $183.69 million, making up 6.11% of all outstanding shares. On the other hand, Smallcap World Fund held roughly 5.98 shares worth around $124.83 million, which represents about 4.15% of the total shares outstanding.
